Appearance
Avelia: Detailed Market Analysis
Date: 2026-03-23 Scope: United States + European Union Audience: Investors, strategic partners, internal product strategy
Section 1: The Problem Landscape
The Trust Collapse in Femtech
The femtech industry is experiencing a structural trust crisis — not a perception problem, but a documented, legally adjudicated failure to protect the most sensitive category of personal data that exists: reproductive health.
In 2021, the FTC settled with Flo Health after the company shared users' pregnancy status with Facebook and Google despite explicit promises not to. In 2023, Stardust — marketed specifically as a "post-Roe safe" period tracker — was exposed for retaining data that could be shared "without legal requirement" per its own Terms of Service. Clue, operating under GDPR in Germany, continued embedding third-party analytics SDKs (Braze, Mixpanel) that receive "technical identifiers" alongside health data. Natural Cycles, FDA-cleared as a contraceptive device, collects basal body temperature, heart rate, and sleep data in a single centralized database — a single point of legal compulsion.
These are not edge cases. They are the business model. Every major competitor monetizes through data: advertising, partnerships, anonymous-but-re-identifiable data sales, or premium upsells powered by behavioral profiling. Privacy is a marketing claim, not a technical guarantee.
The Post-Roe Legal Landscape (US)
The overturning of Roe v. Wade in 2022 and the subsequent state-by-state criminalization of reproductive healthcare transformed reproductive health data from a privacy concern into a legal liability for users. In states where abortion is criminalized, a user's period tracking history, pregnancy test logs, or missed periods are discoverable evidence in criminal prosecutions. Law enforcement has already subpoenaed period tracking data from at least three known cases as of 2025.
The HIPAA 2026 reproductive health amendments attempt to partially address this — prohibiting covered entities from disclosing reproductive health data for criminal investigations — but femtech apps are largely not HIPAA-covered entities. The amendment protects clinic records; it does not protect Flo's servers.
This creates a category of users — concentrated but vocal — for whom "we promise not to share your data" is legally meaningless. Only an architecture that cannot share data satisfies their requirement.
The EU Regulatory Pressure (GDPR Article 9)
In the EU, reproductive health data is classified as a "special category" under GDPR Article 9 — the highest tier of data sensitivity, requiring explicit consent for every processing purpose. Fines for mishandling Article 9 data can reach 4% of global annual turnover. Despite this, EU-based femtech apps routinely embed third-party SDKs, rely on consent banners as their legal basis, and store data in cloud infrastructure accessible to employees and legal authorities.
The EU regulatory environment does not make centralized femtech safe — it makes it expensive and legally precarious. An app that transmits and stores no decrypted health data faces near-zero GDPR exposure on the content of that data — standard obligations around account metadata and authentication records remain, but these carry a fraction of the legal and financial risk of Article 9 special category data. This is a structural competitive moat, not a compliance feature.
The Emotional Weight of the Journey
Beyond legal risk, there is a deeper human truth that the current market ignores: the journey from "considering a family" through early childhood is one of the most emotionally loaded experiences a person can have. Miscarriages, failed IVF cycles, postpartum depression, NICU stays — these are not data points. They are the most private moments of a person's life.
The dominant apps treat these moments as engagement opportunities and training data. Avelia's design premise — that this data belongs only to the person who lived it — is not just a privacy stance. It is a fundamentally different relationship with the user.
Section 2: Market Sizing (US + EU)
The Total Addressable Market
The global femtech market was valued at approximately $6.1 billion in 2024 and is projected to reach $13–16 billion by 2030, growing at a CAGR of roughly 12–14%. However, "femtech" as a category is broad — it includes medical devices, telehealth platforms, and consumer apps. The relevant segment for Avelia is the reproductive health and parenting app market.
Within the US and EU combined, this segment represents:
- ~180 million women of reproductive age (15–49) across the US and EU
- ~12–15 million couples actively trying to conceive or in active pregnancy at any given time in these two markets
- ~5–6 million IVF cycles performed annually in the US and EU combined (a high-intent, high-spend, high-privacy-sensitivity cohort)
The parenting app market (birth through early childhood) adds a further layer: approximately 3.5 million births per year in the US and 4.1 million in the EU, representing a combined cohort of ~20+ million active parents of children under 5 in these markets.
The Serviceable Addressable Market
Avelia's SAM is the subset of these users who are:
- Privacy-aware — actively concerned about data sharing (accelerated by post-Roe discourse and GDPR awareness)
- Couple-oriented — in a committed relationship and wanting to share the journey with a partner
- App-native — willing to use a dedicated mobile app rather than spreadsheets or general-purpose tools
Current market research (2025) suggests approximately 18–22% of femtech app users report privacy as their primary selection criterion — a figure that has grown significantly since 2022. Applied to the combined US+EU reproductive health app userbase (estimated at ~40 million active users), this represents a SAM of approximately 7–9 million users today, expanding as privacy awareness grows.
Avelia's Serviceable Obtainable Market
In a realistic 3-year horizon, Avelia's SOM targets:
- Year 1: 10,000–50,000 users, concentrated in IVF/Assisted communities (high intent, high community density, highest privacy sensitivity)
- Year 2: 100,000–300,000 users, expanding to Trying Naturally and Pregnancy stages via PLG partner-invite loops
- Year 3: 500,000–1,000,000 users, with EU expansion and potential B2B clinic partnerships
The IVF-to-Pregnant stage transition is the key retention hinge: users who achieve a successful pregnancy and continue into Stage 4 represent compounding multi-year LTV. Users who do not progress (failed cycles, ceased treatment) are the primary churn risk at Stage 3. The stage-aware design and emotional tone of Avelia are specifically built to retain this cohort through failure, not only through success.
At Avelia's projected pricing (see Section 6), 500,000 paying users at a blended ARPU of $60–80/year represents $30–40M ARR — a credible outcome for a privacy-differentiated product in a market where trust is the scarcest resource.
Why the Numbers Understate the Opportunity
Standard femtech TAM figures do not account for the suppressed demand created by privacy concerns. A meaningful percentage of users who would use a tracking app do not because they don't trust what happens to their data. This is not speculative: following the Dobbs decision in June 2022, period tracking apps reported a documented spike in account deletions and app store removals, with several news cycles specifically attributing this to data-sharing fears. Avelia's architecture doesn't compete for existing app users — it unlocks a category of users who have opted out of the market entirely. This cohort is structurally invisible in current market sizing but represents genuine greenfield demand.
Section 3: User Segmentation
The Seven Stages as Seven Personas
Avelia's 7-stage model maps directly to distinct user personas with different needs, privacy sensitivities, and willingness to pay.
Stage 1 — Considering Couples in early conversations about family planning. Privacy sensitivity is moderate — they're not yet generating medical data — but emotional sensitivity is high. These users want a judgment-free space for private conversations and values alignment. Competitive alternatives: journaling apps, couples apps (none with stage-awareness). Willingness to pay: low-moderate.
Stage 2 — Trying Naturally The core femtech user. Cycle tracking, ovulation prediction, BBT, fertile window. Privacy sensitivity is high — cycle data is intimate and legally sensitive in the US. This is Flo/Clue's core market, which means it is also where Avelia's privacy differentiation is most directly legible. Willingness to pay: moderate. Community density: high (Reddit r/TryingForABaby has 500k+ members).
Stage 3 — IVF / Assisted The highest-value wedge segment. IVF users are:
- High data sensitivity: Medication schedules, embryo counts, retrieval outcomes, and repeated failure events. This is data users are deeply motivated to protect.
- High willingness to pay: IVF cycles cost $15,000–$25,000 per attempt. An app subscription is rounding error. These users will pay for quality.
- High community density: r/IVF (300k+ members), r/infertility (200k+ members), specialized Discord servers. These communities are active, vocal, and highly responsive to authentic "build in public" engagement.
- High partner inclusion demand: IVF is uniquely bilateral — both partners are medically involved (sperm analysis, coordination, emotional support). No current app treats both partners as first-class users.
Stage 4 — Pregnant Week-by-week tracking, appointment management, birth planning. Privacy sensitivity is highest here — pregnancy status is the most legally sensitive data point in the US post-Dobbs. Users are emotionally invested and highly engaged. The incumbent (The Bump, BabyCenter, Ovia) are ad-supported and data-heavy. Willingness to pay: moderate-high. Retention: near-perfect (nine months of guaranteed engagement).
Stage 5 — Birth & Beyond A brief but emotionally intense stage. Contraction timers, hospital preparation, immediate postpartum. High emotional stakes, low competitive differentiation in existing apps. Users are motivated to document but overwhelmed. Avelia's warm, non-clinical design is a direct response.
Stage 6 — First Year Feeding logs, sleep tracking, growth charts, vaccine schedules. This is where parenting apps dominate (Huckleberry, Baby Tracker). Privacy sensitivity is moderate but increasing as parents become aware of what data companies do with infant behavioral data. Partner inclusion is highest here — sleep deprivation makes shared logging essential. Willingness to pay: high (sleep-deprived parents pay for anything that works).
Stage 7 — Growing Up Milestone tracking, family memory archive. This stage has the longest duration and the lowest engagement frequency. Willingness to pay: lower, but LTV benefit of retaining users from earlier stages is high. Potential for a "Family Memory" premium feature.
The Non-Carrying Partner: The Ignored User
Across all stages, the non-carrying partner is systematically excluded from existing apps. Apps are designed for the person tracking their body — the partner is at best a passive recipient of shared updates. This is a 50% market share left on the table.
Avelia treats the non-carrying partner as a first-class user with their own account, their own logging (mood, support actions, emotional check-ins), and their own privacy controls. In IVF specifically, the partner's experience (sperm analysis anxiety, helplessness during procedures, grief after failed cycles) is entirely unaddressed by every existing app.
This isn't a nice-to-have. It's a structural differentiator that doubles Avelia's potential user count relative to female-only apps.
EU vs. US Behavioral Differences
US users are primarily motivated by the legal/political privacy narrative (post-Roe, law enforcement data requests, FTC history). The fear is concrete and recent. The IVF wedge is strong here — IVF is expensive, emotionally intense, and under-insured, creating a user who is financially stressed and data-protective.
EU users are more GDPR-literate and have a longer history of demanding data sovereignty. They are also more likely to be in countries where reproductive healthcare is publicly funded (reducing cost anxiety) and less likely to face legal criminalisation of reproductive choices. For EU users, Avelia's privacy story shifts from "protect yourself from prosecution" to "your medical data is yours, not a product." The emotional framing differs; the architectural advantage is identical.
Section 4: Competitive Landscape
The "Privacy Theater" Category
The defining feature of Avelia's competitive landscape is not feature gaps — it is a structural honesty gap. Every major competitor has made privacy promises they cannot technically keep, because their architecture requires them to hold user data to function. We call this "Privacy Theater": the performance of privacy without the architecture to back it.
Flo Health The market leader by downloads (~50M+ active users globally). Flo's 2021 FTC settlement — sharing pregnancy status with Facebook and Google despite explicit privacy promises — is the defining incident in femtech data betrayal. Their response was "Anonymous Mode," which is a policy control, not a technical one. Flo employees can still access user data; legal authorities can still compel disclosure. Flo's business model depends on behavioral data to power its AI Health Assistant. Privacy and profitability are structurally in tension. Their vulnerability: the next regulatory action or data breach will hit a user base that has already been betrayed once.
Clue German-based, GDPR-compliant in policy, but not in architecture. Clue embeds Braze and Mixpanel (both US-based analytics companies), meaning EU user behavioral data flows to US servers subject to US legal jurisdiction. Their response to post-Roe concerns was a blog post, not a technical change. Clue is the "thoughtful" option in femtech — their science-first branding resonates with educated EU users — but their architecture cannot support the privacy claims their marketing implies. Their vulnerability: a single GDPR enforcement action or German court order could expose the gap between their messaging and their infrastructure.
Natural Cycles The premium tier competitor. FDA-cleared as a contraceptive device, which creates regulatory credibility but also regulatory constraint — their data collection requirements are mandated by their clearance model. Natural Cycles cannot be privacy-first without losing their core product differentiation. Their vulnerability: the FDA clearance model requires them to be a data company. They are the most honest about this (per their published Privacy Policy and Annual Report), which is why they're also the most exposed when users start asking the right questions.
Stardust Born as a "post-Roe safe" alternative, explicitly marketed on privacy. Their 2022 exposure — that initial E2EE claims were false and their TOS allowed broad data sharing without legal requirement — is the most damaging case study in femtech "Privacy Theater." Users who came to Stardust specifically for privacy were betrayed by the app most loudly claiming to protect them. Stardust's vulnerability: their brand is built on a promise they couldn't keep. Any further scrutiny accelerates user flight. They represent the cautionary tale that validates Avelia's approach.
Ovia Health B2B-focused, selling employer wellness programs. Privacy is irrelevant to their model — employers want aggregate data. Not a direct competitor for privacy-conscious users, but a data point on where "femtech" can go when the user is not the customer.
Avelia's Structural Position
Avelia's competitive moat is not a feature — it is an architectural impossibility. The company cannot comply with a data subpoena for health data content because it does not hold decrypted user data. This is not a policy claim. It is a cryptographic fact. (Standard account metadata — authentication records, partner-link associations — is held and producible under legal compulsion, as it is in any app; what cannot be produced is the health record itself.) No competitor can make this claim because their business models require them to hold and process user data.
This creates an asymmetric competitive dynamic: as regulatory pressure increases (HIPAA 2026, GDPR enforcement, state-level data protection laws), competitors' liabilities grow while Avelia's architectural advantage compounds.
* "Very Low" reflects that account metadata obligations remain (authentication records, partner-link associations) but no health data content is held or producible.
| Dimension | Flo | Clue | Natural Cycles | Stardust | Avelia |
|---|---|---|---|---|---|
| Data stored on company servers | Yes | Yes | Yes | Yes | No |
| Can comply with data subpoena | Yes | Yes | Yes | Yes | No |
| Partner as first-class user | No | No | No | No | Yes |
| Covers full 7-stage journey | No | No | No | No | Yes |
| Expert-reviewed in-app guidance | Partial | Partial | No | No | Yes |
| Expert marketplace w/ data access | No | No | No | No | Yes |
| Business model requires data | Yes | Yes | Yes | Yes | No |
| Post-Roe legal liability | High | Medium | High | High | Very Low* |
Section 5: Regulatory Tailwinds
HIPAA 2026: Reproductive Health Data
The 2026 HIPAA amendments prohibit covered healthcare entities from disclosing reproductive health information for criminal investigations or civil proceedings related to lawful reproductive healthcare. While this protects clinical records, it creates an important secondary effect: it signals federal recognition that reproductive health data is a uniquely sensitive category requiring structural protection, not just policy promises.
For Avelia, this is a tailwind: it legitimizes the privacy-first positioning and raises user awareness of data risks. For competitors, it creates compliance complexity — they must now evaluate whether their data practices comply with the new rules, adding legal overhead and reputational risk.
GDPR Article 9: Special Category Data (EU)
Reproductive health data — menstrual cycles, fertility treatments, pregnancy status — is explicitly classified as "special category" data under GDPR Article 9. Processing this data requires explicit, granular consent for each purpose, and data controllers must implement "appropriate technical and organisational measures" to protect it. The penalty framework (up to 4% of global annual turnover or €20M) creates existential financial risk for mid-sized femtech companies operating in the EU.
The critical insight: GDPR compliance for centralized apps is expensive, legally precarious, and requires ongoing legal maintenance. For Avelia, where no personal health data is ever transmitted or stored in decrypted form, Article 9 compliance is structurally near-guaranteed on data content — standard account metadata obligations (authentication records, account associations) remain, but these are categorically lower-risk than special category health data and require no special legal basis. This dramatically reduces legal overhead and creates a credible "GDPR-native" positioning for EU market entry.
The Post-Dobbs Landscape (US)
At least 14 US states have near-total abortion bans as of 2026, with pending legislation in several more. Law enforcement in these states has sought and received digital evidence in reproductive healthcare cases, including app data, location data, and search histories. The legal precedent for using femtech data in criminal proceedings now exists.
This creates a permanent, structural demand for genuinely private reproductive health tools in the US market — not as a niche feature but as a baseline requirement for a growing segment of users. Avelia's architecture is the only one that meets this requirement categorically.
The Digital Services Act (EU)
The EU's Digital Services Act (DSA) imposes new transparency requirements on algorithmic systems and targeted advertising. Avelia's subscription-only monetization model (no in-app advertising, no behavioral profiling) is fully DSA-compatible by design: there is no ad-targeting system, no algorithmic ranking driven by commercial incentives, and no personal data transmitted to advertisers. As DSA enforcement ramps up in 2026–2027, competitors with ad-based monetization will face compliance overhead that Avelia does not.
Regulatory Risk Assessment
Avelia faces near-zero regulatory risk from data protection enforcement because there is no data to protect against. The primary regulatory risk is the inverse: if regulatory frameworks require apps to hold certain data (e.g., FDA clearance requirements for contraceptive claims), Avelia must navigate those requirements carefully. This constrains certain product directions (e.g., marketing as a contraceptive tool) but does not affect the core product proposition.
Section 6: Avelia's Positioning & GTM
The Core Thesis
The femtech privacy reckoning is not a trend — it is a structural market realignment driven by documented betrayals, legal precedent, and regulatory pressure. The market is bifurcating: apps that monetize user data (the incumbents) and apps that monetize user trust (the opportunity). Avelia is the only product in the second category with the architectural integrity to back the claim and the product breadth to serve the full journey.
The IVF Wedge Strategy
Avelia's go-to-market does not attempt to compete with Flo's 50 million users on day one. The strategy is precision entry into the highest-value, highest-privacy-sensitivity, highest-community-density cohort: the IVF/Assisted community.
IVF users are ideal first adopters because:
- They are active in highly engaged online communities (r/IVF, r/infertility, specialized Discord servers) that are responsive to authentic, technical communication
- Their data sensitivity is non-negotiable — a failed IVF cycle is not a data point to be monetized
- Their willingness to pay is demonstrated (IVF cycles cost $15,000–$25,000; software is not the constraint)
- Their partner inclusion need is the highest of any stage — IVF is a bilateral medical process with high bilateral emotional load
- They move through stages (IVF → Pregnant → First Year) — a successfully retained IVF user becomes a multi-year customer
The acquisition channel is earned trust, not paid acquisition: "build in public" updates in community spaces, a technical privacy whitepaper ("The Sovereign Data Model"), and a public competitor privacy audit. The message is not "we're better than Flo" — it is "we're the only one that physically cannot betray you."
Partner Inclusion as a Growth Loop
Every Avelia user who links a partner doubles the user count with zero acquisition cost. The partner invite is not a referral — it is a deeply emotional ask: "[Name] wants to share this journey with you in a private space." The conversion rate on this invite is structurally higher than any paid channel because the motivation is relational, not transactional.
Partner linking also locks in retention: a couple that is co-logging their IVF protocol is far less likely to churn than a solo user tracking their cycle. The shared data creates a network effect within the partnership unit.
The Guide: Curated Content as a Retention Engine
Avelia includes a dedicated Guide section — curated articles, checklists, and best practices matched to the user's current stage and, where applicable, current week (e.g., Week 16 of pregnancy surfaces Week 16-specific content). This is not a generic health blog. It is an expert-reviewed, stage-aware content layer that makes the app useful beyond logging. No user-generated content appears here; every piece is sourced and vetted.
This matters strategically for three reasons:
- Retention — Users who find weekly guidance valuable develop a daily-check-in habit. A pregnant user who trusts "what to expect this week" is not going to switch apps between trimesters. Content drives session frequency independent of whether the user has something to log.
- Trust signal — Expert-reviewed content positions Avelia as a credible health companion, not just a private notepad. This is the platform quality that earns the right to host an expert marketplace. Competitors with ad-driven content cannot make the same claim — their content strategy is shaped by monetization, not user value.
- Partner engagement — Content explicitly tagged for partners (e.g., "How to support your partner through the two-week wait") gives the non-carrying partner guided, actionable roles at each stage. This drives partner-account retention independent of their own logging activity.
The content layer also creates a natural freemium differentiation ladder: community-standard guides are free; expert-authored premium content (e.g., a doula-authored birth plan builder, an IVF nurse's medication protocol explainer) gates behind the Journey subscription, driving conversion without requiring the user to have experienced a specific feature gate.
Pricing Architecture
Based on 2026 market benchmarks:
| Tier | Price | Positioning |
|---|---|---|
| Free | $0 | Core logging + privacy, limited history, freemium conversion entry point |
| Journey (monthly) | $9.99/mo | Full history, guidance, partner sync |
| Journey (annual) | $69.99/yr | ~$5.83/mo effective — primary conversion target |
| Journey Pass (lifetime) | $149 one-time | Underserved in market; strong for IVF users who want permanence |
The monthly price matches Clue's affordable tier deliberately: it minimises friction at the point of initial paid commitment. The premium proposition is carried by the annual ($69.99/yr vs. Clue's $39) and Lifetime tiers, where users who have demonstrated intent signal it with a materially higher investment. Avelia does not need to win on monthly price — it needs to win on trust, then convert to the higher-value tiers.
The Lifetime Pass is a deliberate positioning move: no major competitor offers it. For IVF users who have just spent $20,000 on a cycle, a one-time $149 purchase for a permanent private record is a trivial decision and a strong signal of Avelia's alignment with their interests (no subscription dependency, no business model incentive to monetize data).
The "Proof of Privacy" Content Strategy
Avelia does not compete on content volume. It competes on technical authority. The two primary content assets are:
The Sovereign Data Whitepaper — a one-page technical explainer of E2EE architecture written for a non-technical audience. Distributed once on Hacker News, Reddit, and LinkedIn. Used as the in-app "About Privacy" page. This document is the most valuable piece of marketing Avelia will ever produce because it is verifiable.
The Competitor Privacy Audit — a factual comparison of competitor privacy architectures, citing FTC settlements, TOS analysis, and SDK audits. Not an opinion piece — a documented record. This positions Avelia as the honest actor in a category of honest-sounding actors.
Expert Partner Network: Clinics, Doulas, and Care Providers
The expert partnership model operates on two levels: distribution (partners as an acquisition channel) and marketplace (partners as a revenue stream).
Distribution — Inbound Referral Channel
IVF clinics, OBGYNs, midwives, doulas, and lactation consultants are natural distribution partners. They interact with exactly the users Avelia targets, at the exact moment those users are most receptive and most data-anxious. A doula who recommends Avelia to a new client is a higher-trust acquisition event than any paid advertisement — and the endorsement message ("the only app I recommend without worrying what they do with your data") is uniquely available to Avelia. No other app can offer a care provider clean hands on that recommendation.
The distribution model is low-friction: vetted partners are listed in-app as "Avelia Partners," receive an attribution link, and earn a revenue share on referred subscriptions. Clinics can co-brand onboarding flows (e.g., "Recommended by [Clinic Name]"), reinforcing both the clinic's patient relationship and Avelia's authority.
Expert Marketplace — Premium Revenue Tier (Year 2+)
The marketplace model unlocks Avelia's highest-potential revenue stream. Models like Maven Clinic demonstrate that users pay $30–75 per session for 1:1 access to doulas, lactation consultants, and fertility specialists. Avelia's structural advantage here is unique and irreplicable by competitors:
With explicit user consent, a user can grant a named expert temporary, scoped, decrypted access to their actual log history. The expert reviews real data before the session — medication compliance logs, embryo tracking, sleep and feeding records — not a verbal summary. No competitor can offer this credibly: their architecture means data is already accessible to the company, so "consent-based access" is just a UI layer over a pre-existing exposure. On Avelia, consent-based expert access is the only access that can ever occur. This is a trust story that sells itself in a clinical context.
The expert session model:
- User books a session with a vetted practitioner (doula, lactation consultant, fertility nutritionist, perinatal mental health counsellor)
- User grants scoped, time-limited read access to relevant log history
- Expert reviews actual data before the session — not a verbal summary, but the real record
- Session occurs in-app or via the expert's preferred channel
- Avelia takes a platform revenue share; the expert builds a client base with no cold-start problem
Expert Content Contributions
Beyond 1:1 sessions, experts contribute authored content to the Guide section — checklists, explainers, and stage-specific best practices written under their professional identity. This:
- Gives experts a distribution channel and professional profile
- Gives Avelia high-quality, credentialed content without an internal content team at scale
- Creates a commercial relationship (revenue share on Guide content that drives Journey conversions) that aligns expert and platform incentives
The expert network is therefore simultaneously an acquisition engine (referrals), a retention driver (content quality), and a premium revenue layer (marketplace sessions) — three functions from a single partner relationship.
Metrics That Matter
| Metric | Target | Why It Matters |
|---|---|---|
| Partner Linking Rate | >50% | Validates the couple-first model; measures PLG loop health |
| Recovery Kit Generation | >80% | Proxy for privacy feature adoption and user trust (Recovery Kit = user's personal E2EE key backup; holding it means the user — not Avelia — controls decryption) |
| Active Logging Rate | >3 entries/week | Measures genuine engagement vs. install-and-forget |
| Guide Engagement Rate | >40% weekly | Validates content as a retention driver; proxy for depth of relationship with the app |
| Stage Retention | >60% cross-stage | IVF → Pregnant → First Year retention validates the journey model |
| Expert Session Bookings | >5% of Journey subscribers | Validates marketplace demand; highest-ARPU revenue event |
| Lifetime Pass Conversion | >5% of paying users | Validates the trust thesis; measures willingness to commit |
Summary: The Investment / Partnership Thesis
Avelia enters a $6+ billion market at the precise moment that market's foundational trust assumption has collapsed. The incumbents cannot fix their privacy problem without breaking their business model. Regulatory pressure (HIPAA 2026, GDPR, post-Dobbs legal precedent) accelerates user awareness and competitor liability simultaneously.
Avelia's architecture is the moat. The product breadth (7 stages, couple-first model) is the retention engine. The IVF community is the wedge. The expert partner network — clinics, doulas, lactation consultants, and care providers — is simultaneously the acquisition channel, the content engine, and the highest-ARPU revenue stream. The Guide section turns a logging app into a trusted health companion that users return to for guidance, not just record-keeping. The Lifetime Pass closes the commitment loop for users who want permanence over subscription.
The opportunity is not to build a better period tracker. It is to become the trusted infrastructure for one of the most significant journeys of a person's life — equipped with the guidance to navigate it, the experts to support it, and an architecture structurally incapable of betraying it.
Sources: FTC v. Flo Health (2021), HIPAA Final Rule on Reproductive Health (2026), GDPR Article 9 (Regulation (EU) 2016/679), EU Digital Services Act (Regulation (EU) 2022/2065), Global Femtech Market Report (2024–2030 projections), r/IVF community member counts (2025), Natural Cycles Annual Report (2024) and Privacy Policy (naturacycles.com), Stardust TOS analysis (2022), post-Dobbs app deletion reporting (June–July 2022, multiple outlets).
Note: "No analytics" and "no third-party SDKs" commitments apply to the Avelia mobile application. The marketing website uses Plausible Analytics (a privacy-preserving, cookie-free tool with no cross-site tracking), which is consistent with the product's privacy principles but is a separate surface from the app.